Seneca Biopharma Inc fka SNCA

[Seel]

Well - one huge question answered is that the procedure doesn't accelerate disease progression. There were indicators in prelim results release some months ago hinting at worsening of progression as a possibility with the procedure. That is the question I most wanted answered. Other results showing about 50% of patients benefit with delayed progression in some areas is not new news - puts us back to the reality the CUR's challenge is to discover in a much more clear and measurable way what differentiates a responder from a non-responder. Someone commented on SA that ALS sufferers would definitely opt for this over Sanofi's drug. Untrue; first because patients have no reason to choose either/or - they can do both. But second - this is a risky procedure with prolonged recovery period. Until CUR can provide better responder guidelines, many patients eligible are likely to not take the risk. If procedure doesn't benefit, they will have lost precious functional time to surgery and recovery.
So - doesn't accelerate progression is huge and valuable news, but it still leaves CUR,investors and patients with need for more markers of the responders.